ESO-Thyr 9A - Medielma

Go to content

Main menu:

ESO-Thyr is a new generation of diagnostic systems for non-invasive, extracorporeal diagnosis of thyroid cancer. ESO-Thyr is a complement to other conventional methods for thyroid cancer detection.
ESO-Thyr high sensitivity and specificity can help to reduce the number of unnecessary biopsies.
ESO-Thyr not only can be used for diagnosis but can be frequently used in the follow-up of thyroid cancer treatments. The thyroid exam is very easy and the outcome is immediately available. The technology is patented, its effectiveness has been proven by scientific publications and it is mature for detection of thyroid cancer.
1. Exploring Probe
The Exploring Probe generates radio frequency waves of very low intensity.

2. Receiver
The Receiver is located under the examination couch and detects the radio frequencies generated by the Exploring Probe. After processing the signal, the Receiver sends the information to a Diagnostic Station.

3. Diagnostic Station
The Diagnostic Station is a Medical PC with a Diagnostic Software that provides the clinician with an easy-to-read diagnostic outcome report.
ESO-Thyr 9A performs ECD Electromagnetic Cancer Detection

Cancer tissues are characterized by several forms of atypical behaviours.
ESO-Thyr 9A is able to detect different electromagnetic properties of malignant tissues in contrast to normal tissues.
ESO-Thyr 9A exams are non-invasive and free of any side effects.
Research on the interaction of electromagnetic with biological tissues dates back to 1920, almost one hundred years ago.
In 1920 the pioneers in the field of radio frequency reported that “malignant cancer tissue has a different behavior than normal tissues or benign tumors”.
The technological advances following the Second World War made it possible to evaluate the biological interaction between blood cells and other biological tissues with radio frequency and microwaves.
In 1970s and 1980s studies continued on comparing malignant cancer tissue relative to the normal adjacent tissues in rats.
In early 2000s a first diagnostic device was designed and made available to the market.
Since then, for over ten years, many trials have been done on thousands of patients and several new products were introduced into the market.
Medielma srl @ 2017  -  Via Ippolito Nievo 28/1, 20145 Milano (Italy)  -  VAT: 07302120964  -  CSV: 117.000 €  -  Phone: +39 02 45498312  -  Mail:
Back to content | Back to main menu